Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL647462 | 0.85 | ERN1 (0.50) | ERN1ALDH1A1SMN1; SMN2CYP2C9MEN1 | |
| SCHEMBL24133365 | 0.81 | ERN1 (0.50) | ERN1 | |
| SCHEMBL30777425 | 0.79 | ERN1 (0.48) | ERN1ALDH1A1SMN1; SMN2CYP2C9MEN1 | |
| SCHEMBL835857 | 0.79 | ERN1 (0.48) | ERN1ALDH1A1SMN1; SMN2CYP2C9MEN1 | |
| SCHEMBL9358193 | 0.79 | CYP1A2 (0.41) | ERN1ALDH1A1SMN1; SMN2CYP2C9MEN1 | |
| SCHEMBL5663380 | 0.75 | CYP1A2 (0.41) | ERN1ALDH1A1SMN1; SMN2CYP2C9MEN1 | |
| SCHEMBL30777418 | 0.75 | MEN1 (0.39) | ERN1ALDH1A1CYP2C9MEN1KMT2A | |
| SCHEMBL21357938 | 0.75 | MEN1 (0.39) | ERN1ALDH1A1CYP2C9MEN1KMT2A | |
| SCHEMBL21730241 | 0.74 | CA1 (0.42) | ALDH1A1CYP2C9MEN1KMT2ACA1 | |
| SCHEMBL834457 | 0.74 | MEN1 (0.50) | ERN1ALDH1A1SMN1; SMN2CYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105610-B | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11560357-B2 | Methods of producing pyrazole compounds | TORRENT PHARMACEUTICALS LIMITED (IN) | 2023-01-24 | — | — | US | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| US-20220033358-A1 | METHODS OF PRODUCING PYRAZOLE COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2022-02-03 | — | — | US | disclosed |
| EP-3853209-A1 | METHODS OF PRODUCING PYRAZOLE COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2021-07-28 | — | — | EP | disclosed |
| CN-113166069-A | Process for producing pyrazole compound | 托伦特药物有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| CN-112105610-A | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| US-8143424-B2 | Thyroid like compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2012-03-27 | — | — | US | disclosed |
| EP-2061766-B1 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS LTD (IN) | 2010-08-18 | — | — | EP | disclosed |
| CN-101772487-A | Novel compound | TORRENT PHARMACEUTICALS LTD | 2010-07-07 | — | — | CN | disclosed |
| US-20100168110-A1 | Novel Compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-07-01 | — | — | US | disclosed |
| US-20100168110-A1 | Novel Compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-07-01 | — | — | US | disclosed |
| EP-2061766-A2 | NOVEL COMPOUNDS | Torrent Pharmaceuticals Ltd (IN) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008149379-A2 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS LTD. (IN) | 2008-12-11 | — | — | WO | disclosed |
| US-7230031-B2 | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-20050085541-A1 | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1471049-A1 | NOVEL THYROID HORMONE RECEPTOR LIGAND, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085541-A1 | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | TSHR, THRA, THRB | ERN1 3194/4885ALDH1A1 3008/4885SMN1; SMN2 4855/4885 |
| US-11560357-B2 | Methods of producing pyrazole compounds | TPO, TSHR, PDXK | ERN1 2512/4885ALDH1A1 526/4885SMN1; SMN2 4811/4885 |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | CD274, PDCD1, PDCD1LG2 | ERN1 2506/4885ALDH1A1 86/4885SMN1; SMN2 2891/4885 |
| US-20220033358-A1 | METHODS OF PRODUCING PYRAZOLE COMPOUNDS | TPO, TSHR, PDXK | ERN1 2512/4885ALDH1A1 526/4885SMN1; SMN2 4811/4885 |
| US-20100168110-A1 | Novel Compounds | TSHR, THRB, GPR119 | ERN1 3029/4885ALDH1A1 1664/4885SMN1; SMN2 4849/4885 |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | CD274, PDCD1, PDCD1LG2 | ERN1 2506/4885ALDH1A1 86/4885SMN1; SMN2 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.